Cargando…

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

We assessed the immunogenicity and safety of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in children in Russian Federation aiming to support the registration of the vaccine in Russia. In this phase 3, non-randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romanenko, Victor, Osipova, Irina, Galustyan, Anna, Scherbakov, Michael, Baudson, Nathalie, Farhi, Déborah, Anaya, Luis, Kuriyakose, Sherine O., Meyer, Nadia, Janssens, Winnie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553713/ https://www.ncbi.nlm.nih.gov/pubmed/32048889 http://dx.doi.org/10.1080/21645515.2020.1720437

Ejemplares similares

1087 Immunogenicity and Safety of 3-Dose Primary Vaccination with Combined DTPa-HBV-IPV/Hib Vaccine in Canadian Aboriginal and non-Aboriginal Infants
por: Scheifele, David W., et al.
Publicado: (2014)

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age
por: Silfverdal, Sven A, et al.
Publicado: (2014)

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants
por: Lalwani, Sanjay K., et al.
Publicado: (2016)

Long-term antibody persistence against hepatitis B in adolescents 14–15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Schwarz, Tino F., et al.
Publicado: (2018)

Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine
por: Bayliss, Julianne, et al.
Publicado: (2020)

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study
por: Kim, Ki Hwan, et al.
Publicado: (2018)

Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Behre, Ulrich, et al.
Publicado: (2016)

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa
por: Vesikari, Timo, et al.
Publicado: (2017)

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study
por: Asatryan, Asmik, et al.
Publicado: (2020)

The Immunogenicity and Safety of a Combined DTaP-IPV//Hib Vaccine Compared with Individual DTaP-IPV and Hib (PRP~T) Vaccines: a Randomized Clinical Trial in South Korean Infants
por: Kang, Jin Han, et al.
Publicado: (2016)

Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2(nd )year of life
por: Steiner, Michael, et al.
Publicado: (2010)

Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models
por: Zhang, Yuntao, et al.
Publicado: (2022)

Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries
por: George, Marina, et al.
Publicado: (2023)

Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China
por: Yin, Zhiying, et al.
Publicado: (2023)

Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants
por: Li, Yanping, et al.
Publicado: (2016)

A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers
por: Quiambao, Beatriz, et al.
Publicado: (2012)

DTaP-IPV-HepB-Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Correction to: DTaP‑IPV‑HepB‑Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants
por: Wilck, Marissa B., et al.
Publicado: (2020)

Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study
por: Anh, Dang Duc, et al.
Publicado: (2015)

A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hib vaccine in healthy adult volunteers in India
por: Sharma, Hitt, et al.
Publicado: (2023)

Simultaneous vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections: A nationwide register based cohort study
por: Sørup, Signe, et al.
Publicado: (2016)

1393. Factors Associated with Co-administration of Pentavalent DTaP-IPV/Hib and Monovalent Hepatitis B Vaccine in the United States (US)
por: Petigara, Tanaz, et al.
Publicado: (2020)

First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age
por: Lindgren, Line M., et al.
Publicado: (2017)

2702. Infants Vaccinated with a Fully-Liquid DTaP-IPV-Hib-HepB Vaccine Are Protected During the High-Risk Period for Haemophilus Influenzae Type B Disease
por: Wilck, Marissa B, et al.
Publicado: (2019)

Is Hib Vaccine of Economic Value in South Korea?
por: Griffiths, Ulla K., et al.
Publicado: (2009)

Hib Vaccines: Past, Present, and Future Perspectives
por: Zarei, Adi Essam, et al.
Publicado: (2016)

Lagging Immune Response to Haemophilus influenzae Serotype b (Hib) Conjugate Vaccine after the Primary Vaccination with Hib of Infants in The Netherlands
por: Schouls, Leo, et al.
Publicado: (2020)

Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)
por: Li, Zhuofan, et al.
Publicado: (2018)

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
por: Kovac, Martina, et al.
Publicado: (2018)

Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously
por: Ahonen, Anitta, et al.
Publicado: (2022)

Post-Marketing Safety Surveillance of a Childhood Pentavalent Diphtheria–Tetanus–Acellular Pertussis–Polio and Haemophilus influenzae Type B (DTaP-IPV//Hib) Vaccine in South Korea
por: Yang, Kuhyun, et al.
Publicado: (2022)

Authors' Reply to "Is Hib Vaccine of Economic Value in South Korea?"
por: Shin, Sangjin, et al.
Publicado: (2009)

Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease
por: Gilsdorf, Janet R
Publicado: (2021)

Vial usage, device dead space, vaccine wastage, and dose accuracy of intradermal delivery devices for inactivated poliovirus vaccine (IPV)
por: Jarrahian, Courtney, et al.
Publicado: (2017)

Implications of private sector Hib vaccine coverage for the introduction of public sector Hib-containing pentavalent vaccine in India: evidence from retrospective time series data
por: Sharma, Abhishek, et al.
Publicado: (2015)

Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial
por: Rivera, Luis, et al.
Publicado: (2017)

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study
por: Van Damme, Pierre, et al.
Publicado: (2010)

Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India
por: Mangarule, S, et al.
Publicado: (2022)

IPVS Policy statement on safety of HPV vaccines
por: .
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6n1s225npc93cuhffhf9rdke6e